PMC:7546120 / 3590-3982 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T25","span":{"begin":209,"end":219},"obj":"Body_part"}],"attributes":[{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma5034"}],"text":"With respect to the SARS-CoV-2 pneumonia, review of literature reveals the prevalence of pleural effusion can be as high as 14% in patients.3–5 In one of the largest trials, Li et al.3 described intrathoracic lymph node enlargement in 67% of cases and pleural effusion in 14% of cases. Patients with more severe cases have a higher prevalence of both lymphadenopathy and pleural effusions.3–5"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T27","span":{"begin":89,"end":105},"obj":"Body_part"},{"id":"T28","span":{"begin":209,"end":219},"obj":"Body_part"},{"id":"T29","span":{"begin":209,"end":214},"obj":"Body_part"},{"id":"T30","span":{"begin":252,"end":268},"obj":"Body_part"},{"id":"T31","span":{"begin":371,"end":388},"obj":"Body_part"}],"attributes":[{"id":"A27","pred":"uberon_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/UBERON_0000175"},{"id":"A28","pred":"uberon_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/UBERON_0000029"},{"id":"A29","pred":"uberon_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/UBERON_0002391"},{"id":"A30","pred":"uberon_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/UBERON_0000175"},{"id":"A31","pred":"uberon_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/UBERON_0000175"}],"text":"With respect to the SARS-CoV-2 pneumonia, review of literature reveals the prevalence of pleural effusion can be as high as 14% in patients.3–5 In one of the largest trials, Li et al.3 described intrathoracic lymph node enlargement in 67% of cases and pleural effusion in 14% of cases. Patients with more severe cases have a higher prevalence of both lymphadenopathy and pleural effusions.3–5"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T22","span":{"begin":20,"end":28},"obj":"Disease"},{"id":"T23","span":{"begin":31,"end":40},"obj":"Disease"},{"id":"T24","span":{"begin":351,"end":366},"obj":"Disease"}],"attributes":[{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0005833"}],"text":"With respect to the SARS-CoV-2 pneumonia, review of literature reveals the prevalence of pleural effusion can be as high as 14% in patients.3–5 In one of the largest trials, Li et al.3 described intrathoracic lymph node enlargement in 67% of cases and pleural effusion in 14% of cases. Patients with more severe cases have a higher prevalence of both lymphadenopathy and pleural effusions.3–5"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T48","span":{"begin":89,"end":105},"obj":"http://purl.obolibrary.org/obo/UBERON_0000175"},{"id":"T49","span":{"begin":140,"end":143},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T50","span":{"begin":174,"end":176},"obj":"http://purl.obolibrary.org/obo/CLO_0001022"},{"id":"T51","span":{"begin":174,"end":176},"obj":"http://purl.obolibrary.org/obo/CLO_0007314"},{"id":"T52","span":{"begin":209,"end":219},"obj":"http://purl.obolibrary.org/obo/UBERON_0000029"},{"id":"T53","span":{"begin":252,"end":268},"obj":"http://purl.obolibrary.org/obo/UBERON_0000175"},{"id":"T54","span":{"begin":323,"end":324},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T55","span":{"begin":371,"end":388},"obj":"http://purl.obolibrary.org/obo/UBERON_0000175"},{"id":"T56","span":{"begin":389,"end":392},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"}],"text":"With respect to the SARS-CoV-2 pneumonia, review of literature reveals the prevalence of pleural effusion can be as high as 14% in patients.3–5 In one of the largest trials, Li et al.3 described intrathoracic lymph node enlargement in 67% of cases and pleural effusion in 14% of cases. Patients with more severe cases have a higher prevalence of both lymphadenopathy and pleural effusions.3–5"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T5","span":{"begin":174,"end":176},"obj":"Chemical"}],"attributes":[{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_30145"}],"text":"With respect to the SARS-CoV-2 pneumonia, review of literature reveals the prevalence of pleural effusion can be as high as 14% in patients.3–5 In one of the largest trials, Li et al.3 described intrathoracic lymph node enlargement in 67% of cases and pleural effusion in 14% of cases. Patients with more severe cases have a higher prevalence of both lymphadenopathy and pleural effusions.3–5"}

{"project":"LitCovid-sentences","denotations":[{"id":"T29","span":{"begin":0,"end":285},"obj":"Sentence"},{"id":"T30","span":{"begin":286,"end":392},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"With respect to the SARS-CoV-2 pneumonia, review of literature reveals the prevalence of pleural effusion can be as high as 14% in patients.3–5 In one of the largest trials, Li et al.3 described intrathoracic lymph node enlargement in 67% of cases and pleural effusion in 14% of cases. Patients with more severe cases have a higher prevalence of both lymphadenopathy and pleural effusions.3–5"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T18","span":{"begin":31,"end":40},"obj":"Phenotype"},{"id":"T19","span":{"begin":89,"end":105},"obj":"Phenotype"},{"id":"T20","span":{"begin":252,"end":268},"obj":"Phenotype"},{"id":"T21","span":{"begin":351,"end":366},"obj":"Phenotype"},{"id":"T22","span":{"begin":371,"end":388},"obj":"Phenotype"}],"attributes":[{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A19","pred":"hp_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/HP_0002202"},{"id":"A20","pred":"hp_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/HP_0002202"},{"id":"A21","pred":"hp_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/HP_0002716"},{"id":"A22","pred":"hp_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/HP_0002202"}],"text":"With respect to the SARS-CoV-2 pneumonia, review of literature reveals the prevalence of pleural effusion can be as high as 14% in patients.3–5 In one of the largest trials, Li et al.3 described intrathoracic lymph node enlargement in 67% of cases and pleural effusion in 14% of cases. Patients with more severe cases have a higher prevalence of both lymphadenopathy and pleural effusions.3–5"}

{"project":"LitCovid-PubTator","denotations":[{"id":"87","span":{"begin":131,"end":139},"obj":"Species"},{"id":"88","span":{"begin":286,"end":294},"obj":"Species"},{"id":"89","span":{"begin":20,"end":40},"obj":"Disease"},{"id":"90","span":{"begin":89,"end":105},"obj":"Disease"},{"id":"91","span":{"begin":252,"end":268},"obj":"Disease"},{"id":"92","span":{"begin":351,"end":366},"obj":"Disease"},{"id":"93","span":{"begin":371,"end":388},"obj":"Disease"}],"attributes":[{"id":"A87","pred":"tao:has_database_id","subj":"87","obj":"Tax:9606"},{"id":"A88","pred":"tao:has_database_id","subj":"88","obj":"Tax:9606"},{"id":"A89","pred":"tao:has_database_id","subj":"89","obj":"MESH:C000657245"},{"id":"A90","pred":"tao:has_database_id","subj":"90","obj":"MESH:D010996"},{"id":"A91","pred":"tao:has_database_id","subj":"91","obj":"MESH:D010996"},{"id":"A92","pred":"tao:has_database_id","subj":"92","obj":"MESH:D008206"},{"id":"A93","pred":"tao:has_database_id","subj":"93","obj":"MESH:D010996"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"With respect to the SARS-CoV-2 pneumonia, review of literature reveals the prevalence of pleural effusion can be as high as 14% in patients.3–5 In one of the largest trials, Li et al.3 described intrathoracic lymph node enlargement in 67% of cases and pleural effusion in 14% of cases. Patients with more severe cases have a higher prevalence of both lymphadenopathy and pleural effusions.3–5"}

{"project":"2_test","denotations":[{"id":"32936903-32394279-133098630","span":{"begin":142,"end":143},"obj":"32394279"},{"id":"32936903-32394279-133098631","span":{"begin":183,"end":184},"obj":"32394279"},{"id":"32936903-32394279-133098632","span":{"begin":391,"end":392},"obj":"32394279"}],"text":"With respect to the SARS-CoV-2 pneumonia, review of literature reveals the prevalence of pleural effusion can be as high as 14% in patients.3–5 In one of the largest trials, Li et al.3 described intrathoracic lymph node enlargement in 67% of cases and pleural effusion in 14% of cases. Patients with more severe cases have a higher prevalence of both lymphadenopathy and pleural effusions.3–5"}